Datasets:
Haley Delamora
Haley-Delamora/
ImmuneCheckpointInhibitor
0
Downloads: 1
[f0cced]: / NLR, TMB and outcomes in patients treated with ICI - Dataset public.xlsx

Download this file

# ID Cohort Year of ICI treatment start Age at ICI start Sex Cancer type NLR MSI type TMB (Mutations/Mb) ICI drug class Best Response Response to ICI Clinical Benefit with ICI Progression Progression-Free Survival (Months) Vital status Overall Survival (Months) Stage at ICI start ICI line of treatment ECOG PS
1 8213 Initial 2017 61 - 65 Female Colorectal 7.6 nan 4.9 PD-1/PD-L1 PD No No Yes 0.92 Dead 5.62 IV Subsequent-line 0.0
2 8214 Initial 2018 66 - 70 Female Endometrial 1.19 Unstable 32.5 PD-1/PD-L1 PR Yes Yes No 15.64 Alive 15.74 IV Subsequent-line 1.0
3 8215 Initial 2018 61 - 65 Female SCLC 1.38 Stable 19.3 PD-1/PD-L1 PR Yes Yes Yes 3.45 Alive 9.59 IV Subsequent-line 0.0
4 8216 Initial 2015 56 - 60 Female Melanoma 2.69 Stable 1.0 Combo PD No No Yes 0.56 Alive 50.14 IV First-line 0.0
5 8217 Initial 2018 51 - 55 Female NSCLC 2.54 Stable 10.5 PD-1/PD-L1 PR Yes Yes Yes 4.67 Alive 9.99 IV Subsequent-line 0.0
6 8218 Initial 2017 66 - 70 Female Hepatobiliary 3.32 nan 6.1 PD-1/PD-L1 PD No No Yes 1.91 Dead 6.05 IV Subsequent-line 0.0
7 8219 Initial 2017 51 - 55 Male Gastric 5.21 Stable 0.0 PD-1/PD-L1 PR Yes Yes Yes 8.61 Dead 18.83 IV First-line 0.0
8 8220 Initial 2015 61 - 65 Female NSCLC 3.89 Stable 2.0 PD-1/PD-L1 PD No No Yes 0.99 Dead 1.64 IV Subsequent-line nan
9 8221 Initial 2016 61 - 65 Female Pancreatic 2.18 Indeterminate 2.0 PD-1/PD-L1 PD No No Yes 1.25 Dead 2.33 IV Subsequent-line 1.0
10 8222 Initial 2017 51 - 55 Male Renal 4.62 Stable 4.4 PD-1/PD-L1 PD No No Yes 1.97 Dead 3.12 IV Subsequent-line 1.0
11 10234 Initial 2016 71 - 75 Female Melanoma 4.54 Stable 3.9 PD-1/PD-L1 CR Yes Yes No 40.44 Alive 40.44 nan First-line 1.0
12 8223 Initial 2017 66 - 70 Female Colorectal 2.56 Indeterminate 41.3 PD-1/PD-L1 SD No No Yes 7.13 Dead 7.13 IV Subsequent-line 0.0
13 8224 Initial 2017 76 - 80 Female Hepatobiliary 3.16 nan 6.1 PD-1/PD-L1 PD No No Yes 0.82 Dead 3.81 IV Subsequent-line 1.0
14 8225 Initial 2017 66 - 70 Male Bladder 1.88 nan 8.8 PD-1/PD-L1 PD No No Yes 1.84 Dead 2.37 IV First-line 0.0
15 8226 Initial 2018 61 - 65 Male SCLC 4.89 Stable 3.5 Combo PD No No Yes 1.35 Alive 3.22 IV Subsequent-line 1.0
16 8227 Initial 2017 61 - 65 Female Sarcoma 4.63 Stable 5.3 PD-1/PD-L1 PD No No Yes 1.74 Dead 18.23 IV Subsequent-line 1.0
17 8228 Initial 2017 66 - 70 Female SCLC 4.88 nan 7.0 Combo PD No No Yes 1.08 Dead 9.33 IV Subsequent-line 1.0
18 8229 Initial 2015 51 - 55 Female NSCLC 2.92 Stable 19.7 PD-1/PD-L1 CR Yes Yes No 45.96 Alive 48.82 IV Subsequent-line 1.0
19 8230 Initial 2017 66 - 70 Male Bladder 4.25 Stable 8.8 PD-1/PD-L1 PD No No Yes 1.64 Dead 6.77 IV Subsequent-line 1.0
20 8231 Initial 2018 91 - 95 Female Endometrial 4.0 Unstable 32.5 PD-1/PD-L1 CR Yes Yes No 14.26 Alive 15.05 IV First-line 0.0
21 8232 Initial 2018 61 - 65 Female NSCLC 8.5 Stable 14.0 PD-1/PD-L1 SD No No Yes 5.32 Dead 5.52 IV First-line 1.0
22 8233 Initial 2018 76 - 80 Female SCLC 5.4 Indeterminate 15.8 PD-1/PD-L1 SD No No Yes 14.26 Alive 16.1 IV Subsequent-line 0.0
23 8235 Initial 2016 51 - 55 Female Bladder 2.56 nan 1.0 PD-1/PD-L1 PD No No Yes 0.53 Dead 2.92 IV Subsequent-line 2.0
24 8236 Initial 2017 61 - 65 Female Endometrial 3.4 Stable 0.9 PD-1/PD-L1 SD No Yes Yes 13.67 Alive 19.94 IV Subsequent-line 0.0
25 8237 Initial 2017 76 - 80 Female NSCLC 5.45 nan 6.1 PD-1/PD-L1 PD No No Yes 1.84 Dead 1.94 IV Subsequent-line 1.0
26 8238 Initial 2017 76 - 80 Male NSCLC 5.75 Stable 14.9 PD-1/PD-L1 PR Yes Yes Yes 9.26 Alive 9.33 IV Subsequent-line 1.0
27 8239 Initial 2017 81 - 85 Female Esophageal 1.0 Unstable 24.6 PD-1/PD-L1 PD No No Yes 1.15 Dead 7.89 IV Subsequent-line 2.0
28 8241 Initial 2018 61 - 65 Male NSCLC 4.43 Stable 7.9 PD-1/PD-L1 PD No No Yes 0.59 Dead 6.01 IV First-line 1.0
29 8242 Initial 2018 56 - 60 Female Renal 3.0 Stable 3.5 PD-1/PD-L1 SD No No Yes 4.93 Alive 10.18 IV Subsequent-line 0.0
30 8243 Initial 2018 66 - 70 Female NSCLC 6.56 Stable 3.5 Combo PD No No Yes 0.92 Dead 4.5 IV Subsequent-line 1.0
31 8244 Initial 2018 71 - 75 Male Gastric 6.14 Stable 11.4 PD-1/PD-L1 PD No No Yes 1.45 Alive 12.29 IV Subsequent-line 1.0
32 8245 Initial 2018 81 - 85 Female NSCLC 8.5 Stable 3.5 PD-1/PD-L1 PR Yes Yes Yes 8.08 Alive 13.54 IV Subsequent-line 1.0
33 8246 Initial 2017 61 - 65 Female NSCLC 2.72 Stable 9.7 PD-1/PD-L1 PR Yes Yes Yes 6.11 Alive 27.27 IV First-line nan
34 8247 Initial 2016 71 - 75 Male NSCLC 3.23 nan 7.0 Combo SD No No Yes 2.46 Dead 13.9 IV First-line 0.0
35 8248 Initial 2015 61 - 65 Male Bladder 5.64 Stable 12.8 Combo CR Yes Yes No 38.41 Alive 38.64 IV First-line 1.0
36 8251 Initial 2016 86 - 90 Female NSCLC 2.33 nan 3.5 PD-1/PD-L1 PR Yes Yes Yes 12.88 Dead 25.49 IV First-line 0.0
37 8252 Initial 2017 56 - 60 Male Colorectal 2.63 Unstable 50.9 PD-1/PD-L1 SD No Yes Yes 11.17 Alive 17.38 IV Subsequent-line 0.0
38 8253 Initial 2016 61 - 65 Female Endometrial 7.4 Stable 0.0 PD-1/PD-L1 PR Yes Yes Yes 3.68 Dead 13.83 IV Subsequent-line 1.0
39 8254 Initial 2017 51 - 55 Female Colorectal 7.0 Stable 3.9 PD-1/PD-L1 PD No No Yes 1.02 Dead 2.17 IV Subsequent-line 1.0
40 8256 Initial 2017 61 - 65 Female Melanoma 6.02 Stable 3.5 PD-1/PD-L1 SD No No Yes 4.14 Dead 18.6 IV First-line 0.0
41 8257 Initial 2016 66 - 70 Male Melanoma 1.9 Stable 7.9 PD-1/PD-L1 SD No No Yes 2.73 Alive 36.4 nan First-line 1.0
42 8258 Initial 2016 76 - 80 Male NSCLC 13.2 Stable 2.0 PD-1/PD-L1 PD No No Yes 1.38 Dead 2.69 IV Subsequent-line 1.0
43 8259 Initial 2016 46 - 50 Female Renal 7.5 Stable 3.9 PD-1/PD-L1 PD No No Yes 1.71 Dead 4.63 IV Subsequent-line 1.0
44 8260 Initial 2018 46 - 50 Male Pancreatic 6.67 Stable 3.5 PD-1/PD-L1 PD No No Yes 1.25 Dead 2.89 IV Subsequent-line 1.0
45 8261 Initial 2017 66 - 70 Female Head & Neck 4.46 Stable 17.6 PD-1/PD-L1 PD No No Yes 3.98 Alive 10.15 IV Subsequent-line 1.0
46 8262 Initial 2018 61 - 65 Male Esophageal 9.09 Stable 5.3 PD-1/PD-L1 PD No No Yes 0.13 Dead 0.13 IV Subsequent-line 1.0
47 8263 Initial 2017 51 - 55 Female NSCLC 10.14 Stable 7.9 PD-1/PD-L1 SD No No Yes 3.52 Dead 16.13 IV Subsequent-line 1.0
48 8264 Initial 2018 61 - 65 Female Gastric 6.0 Stable 5.3 Combo PD No No Yes 0.95 Dead 0.95 IV Subsequent-line 1.0
49 8265 Initial 2018 81 - 85 Male NSCLC 1.81 Stable 2.0 PD-1/PD-L1 PD No No Yes 3.61 Alive 10.91 IV Subsequent-line nan
50 8266 Initial 2017 56 - 60 Female SCLC 2.32 Stable 10.5 Combo CR Yes Yes No 27.37 Alive 30.13 IV Subsequent-line 0.0
51 8267 Initial 2016 66 - 70 Female NSCLC 3.27 Stable 12.8 PD-1/PD-L1 SD No No Yes 0.85 Dead 0.85 IV First-line 0.0
52 8268 Initial 2017 51 - 55 Female NSCLC 1.32 nan 2.0 PD-1/PD-L1 PR Yes Yes No 20.73 Alive 20.73 IV First-line nan
53 8270 Initial 2017 66 - 70 Female Ovarian 2.25 nan 1.8 PD-1/PD-L1 SD No No Yes 2.53 Dead 7.06 IV Subsequent-line 0.0
54 8272 Initial 2018 66 - 70 Female NSCLC 23.0 Stable 9.7 PD-1/PD-L1 PD No No Yes 0.39 Dead 0.39 IV Subsequent-line 1.0
55 8273 Initial 2018 76 - 80 Female Endometrial 0.92 Unstable 29.8 PD-1/PD-L1 PD No No Yes 2.76 Dead 11.27 IV Subsequent-line 0.0
56 8274 Initial 2017 61 - 65 Male Bladder 11.5 Stable 13.2 PD-1/PD-L1 SD No No Yes 3.06 Alive 24.77 IV First-line 2.0
57 8275 Initial 2018 76 - 80 Female NSCLC 2.0 Stable 4.4 PD-1/PD-L1 PD No No Yes 2.43 Dead 8.25 IV Subsequent-line 1.0
58 8276 Initial 2017 56 - 60 Male Renal 3.28 Stable 0.0 PD-1/PD-L1 PR Yes Yes Yes 11.24 Alive 19.38 IV Subsequent-line 1.0
59 8277 Initial 2018 61 - 65 Male Gastric 5.2 Stable 4.4 PD-1/PD-L1 PD No No Yes 3.32 Dead 4.21 IV Subsequent-line 2.0
60 8278 Initial 2016 71 - 75 Male Melanoma 5.88 nan 36.0 PD-1/PD-L1 CR Yes Yes No 38.51 Alive 38.51 IV First-line 0.0
61 8279 Initial 2018 81 - 85 Male NSCLC 14.4 Stable 6.1 PD-1/PD-L1 PD No No Yes 1.38 Alive 5.26 IV Subsequent-line 2.0
62 8280 Initial 2017 51 - 55 Female NSCLC 3.38 nan 8.9 Combo PR Yes Yes Yes 5.68 Alive 9.56 IV Subsequent-line 1.0
63 8281 Initial 2017 86 - 90 Male Bladder 3.56 Indeterminate 4.4 PD-1/PD-L1 SD No No Yes 4.07 Dead 12.12 IV First-line 1.0
64 8283 Initial 2017 76 - 80 Male Melanoma 1.91 nan 36.0 Combo SD No No Yes 2.3 Alive 28.68 IV First-line nan
65 8284 Initial 2018 71 - 75 Female NSCLC 33.75 Stable 11.4 PD-1/PD-L1 PD No No Yes 1.61 Dead 6.6 IV First-line 1.0
66 8285 Initial 2016 71 - 75 Male Pancreatic 3.79 Stable 9.8 PD-1/PD-L1 PD No No Yes 0.72 Dead 4.63 IV Subsequent-line 0.0
67 8286 Initial 2017 86 - 90 Male NSCLC 2.6 Stable 1.8 PD-1/PD-L1 PR Yes Yes No 24.8 Alive 25.0 IV First-line 1.0
68 8287 Initial 2017 46 - 50 Female Breast 1.77 Stable 3.5 PD-1/PD-L1 SD No No Yes 5.29 Dead 20.07 III Subsequent-line nan
69 8288 Initial 2018 46 - 50 Female Renal 4.9 Stable 4.4 PD-1/PD-L1 PR Yes Yes No 9.66 Alive 9.69 IV Subsequent-line 0.0
70 8289 Initial 2018 71 - 75 Female SCLC 5.2 Stable 10.5 Combo SD No No Yes 4.9 Dead 7.79 IV Subsequent-line 1.0
71 8290 Initial 2017 61 - 65 Male Hepatobiliary 4.0 Stable 3.9 PD-1/PD-L1 PR Yes Yes Yes 14.55 Alive 26.84 IV Subsequent-line 1.0
72 8291 Initial 2015 51 - 55 Male Renal 2.57 Stable 8.9 Combo PR Yes Yes No 46.46 Alive 46.92 IV First-line 0.0
73 8292 Initial 2016 46 - 50 Male Renal 4.55 Stable 3.0 PD-1/PD-L1 PD No No Yes 1.38 Dead 13.21 IV Subsequent-line 0.0
74 8293 Initial 2016 36 - 40 Male Pancreatic 6.25 Stable 3.0 PD-1/PD-L1 PD No No Yes 1.68 Dead 14.16 IV Subsequent-line 0.0
75 8294 Initial 2017 76 - 80 Male Bladder 1.1 nan 9.7 PD-1/PD-L1 PD No No Yes 2.23 Dead 12.06 IV Subsequent-line 0.0
76 8295 Initial 2016 71 - 75 Female NSCLC 3.67 Stable 30.5 PD-1/PD-L1 PR Yes Yes Yes 14.36 Alive 39.56 IV Subsequent-line 0.0
77 8296 Initial 2016 46 - 50 Female NSCLC 1.44 nan 7.0 PD-1/PD-L1 PD No No Yes 2.1 Dead 10.05 IV Subsequent-line nan
78 8297 Initial 2015 66 - 70 Male NSCLC 6.08 Stable 39.4 PD-1/PD-L1 PD No No Yes 1.74 Dead 20.93 IV Subsequent-line 1.0
79 8298 Initial 2015 51 - 55 Male Melanoma 3.83 Stable 49.2 Combo CR Yes Yes No 52.44 Alive 52.44 IV First-line 0.0
80 8299 Initial 2017 46 - 50 Female NSCLC 2.95 Stable 5.9 PD-1/PD-L1 PD No No Yes 1.28 Alive 20.44 IV Subsequent-line 1.0
81 8300 Initial 2017 41 - 45 Male Hepatobiliary 21.8 Stable 4.9 PD-1/PD-L1 PD No No Yes 0.3 Dead 0.33 IV Subsequent-line 2.0
82 8301 Initial 2017 61 - 65 Female Sarcoma 4.6 Stable 2.6 Combo PD No No Yes 1.54 Alive 21.78 IV Subsequent-line 0.0
83 8303 Initial 2015 61 - 65 Male NSCLC 14.8 Stable 3.0 PD-1/PD-L1 PD No No Yes 0.03 Dead 0.03 IV Subsequent-line nan
84 8304 Initial 2017 51 - 55 Male NSCLC 13.9 Stable 9.7 PD-1/PD-L1 PD No No Yes 0.69 Dead 12.12 IV Subsequent-line 0.0
85 8306 Initial 2015 51 - 55 Male Melanoma 20.75 Stable 4.4 PD-1/PD-L1 PD No No Yes 1.35 Dead 35.75 IV First-line 0.0
86 8307 Initial 2015 41 - 45 Female Renal 3.29 Stable 6.9 Combo CR Yes Yes No 51.75 Alive 51.75 IV First-line 0.0
87 8308 Initial 2016 56 - 60 Male NSCLC 5.33 Stable 3.0 PD-1/PD-L1 PD No No Yes 1.45 Dead 7.62 IV Subsequent-line 0.0
88 8309 Initial 2017 66 - 70 Female NSCLC 6.29 Stable 1.0 PD-1/PD-L1 PD No No Yes 0.85 Dead 3.35 IV Subsequent-line 2.0
89 8310 Initial 2015 56 - 60 Female NSCLC 3.25 Stable 5.9 PD-1/PD-L1 PR Yes Yes No 50.23 Alive 52.04 IV Subsequent-line 0.0
90 8311 Initial 2015 81 - 85 Male Melanoma 7.88 Indeterminate 102.3 PD-1/PD-L1 PR Yes Yes Yes 6.44 Dead 27.47 IV First-line 0.0
91 8312 Initial 2015 76 - 80 Female Head & Neck 34.5 Stable 3.9 CTLA-4 PD No No Yes 0.43 Dead 1.54 IV Subsequent-line 1.0
92 8313 Initial 2015 56 - 60 Female NSCLC 2.25 Stable 4.9 PD-1/PD-L1 PR Yes Yes Yes 8.51 Dead 31.47 IV Subsequent-line 0.0
93 8314 Initial 2016 46 - 50 Female NSCLC 1.5 Stable 4.9 PD-1/PD-L1 PR Yes Yes Yes 24.31 Alive 32.85 IV Subsequent-line 1.0
94 8315 Initial 2018 36 - 40 Female NSCLC 1.38 Stable 3.0 PD-1/PD-L1 SD No No No 7.13 Alive 12.52 IV Subsequent-line 0.0
95 8316 Initial 2015 56 - 60 Female Melanoma 2.3 Stable 3.0 PD-1/PD-L1 PR Yes Yes Yes 10.41 Alive 11.07 IV First-line 0.0
96 8317 Initial 2015 76 - 80 Male Melanoma 4.67 Stable 10.8 PD-1/PD-L1 PD No No Yes 1.61 Dead 3.25 IV First-line 1.0
97 10235 Initial 2016 46 - 50 Female Mesothelioma 8.43 Stable 0.0 PD-1/PD-L1 PD No No Yes 0.89 Dead 2.23 III Subsequent-line 1.0
98 8318 Initial 2015 56 - 60 Female NSCLC 9.43 Stable 4.9 Combo SD No No Yes 5.06 Dead 27.96 IV First-line 1.0
99 8319 Initial 2015 21 - 25 Male Melanoma 5.82 Stable 9.8 Combo PR Yes Yes Yes 13.31 Alive 49.91 III First-line 0.0
100 8320 Initial 2015 61 - 65 Male NSCLC 28.2 Stable 13.8 PD-1/PD-L1 SD No No Yes 3.12 Dead 3.68 IV Subsequent-line 1.0